Physician profile
Anne E Rodrigue
NPI 1295962165
$4,609.34
in general payments reported to CMS, 2019-2025
29 companies · $2,373 in 2025
The $2,373 reported for 2025 was more than what 95% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $355 · 2020: $15.60 · 2021: $140 · 2022: $649 · 2023: $621 · 2024: $456 · 2025: $2,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,080 · Food and Beverage: $1,285 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,080.00 |
| Food and Beverage | $1,284.71 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $2,080.00 | 2025 | Zurzuvae |
| Abbvie INC. | $469.53 | 2019-2023 | Liletta, Lo Loestrin Fe, Orilissa |
| Astellas Pharma US INC | $319.28 | 2021-2025 | Veozah |
| Exeltis, USA INC. | $226.03 | 2019-2025 | Slynd |
| Pfizer INC. | $213.18 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $206.44 | 2023-2025 | Myfembree, Gemtesa |
| Amgen INC. | $176.02 | 2019-2025 | Evenity, Prolia, Prolia |
| Mayne Pharma Commercial LLC | $161.15 | 2022-2025 | |
| Hologic Sales and Service, LLC | $93.96 | 2019-2023 | Aptima |
| Revvity, INC. | $67.27 | 2023 | |
| Avion Pharmaceuticals | $58.75 | 2019-2023 | Balcoltra |
| Myovant Sciences INC. | $57.27 | 2021-2022 | |
| Aspira Women'S Health INC | $52.87 | 2021-2022 | |
| Agile Therapeutics, INC. | $50.86 | 2021-2022 | |
| Smith+Nephew, INC. | $47.85 | 2022-2023 | Stravix Pl |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $43.93 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.38 | 2022-2025 | |
| Mylan Pharmaceuticals INC. | $31.73 | 2022 | |
| Davol INC. | $29.18 | 2023 | Arista Ah Flexitip |
| Virtus Pharmaceuticals LLC | $25.70 | 2021 | |
| Organon LLC | $24.54 | 2022-2023 | Nexplanon |
| Coloplast Corp | $22.81 | 2019 | |
| Sage Therapeutics, LLC | $22.60 | 2024 | |
| Millicent US INC | $20.43 | 2024 | Femring, Intrarosa |
| Urovant Sciences INC | $19.74 | 2022 | |
| Vertical Pharmaceuticals, LLC | $17.38 | 2019 | |
| Merck Sharp & Dohme LLC | $14.25 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.64 | 2019 | |
| Evofem Biosciences, INC. | $10.57 | 2025 | Solosec, Phexx, Phexxi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Rodrigue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.